Even in worst-case scenario, Roche will grow past biosimilar erosion in the U.S.: executive

17th October 2018 Uncategorised 0

Roche’s trio of megablockbuster cancer drugs, Herceptin, Rituxan and Avastin, are expected to face copycats in the U.S. in 2019, but a bullish management team said Wednesday that sales will grow “even in a worst-case scenario,” thanks to new drugs like multiple sclerosis star Ocrevus.

More: Even in worst-case scenario, Roche will grow past biosimilar erosion in the U.S.: executive
Source: fierce